<DOC>
	<DOCNO>NCT00329004</DOCNO>
	<brief_summary>The purpose research study determine high dose drug ( BMS-690514 ) safely give patient advanced cancer .</brief_summary>
	<brief_title>A Phase I Study BMS-690514 Patients With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Men woman 18 old Diagnosis solid tumor ECOG performance status score 01 Prior chemotherapy , immunotherapy radiotherapy least 4 week since last treatment Treatment VEGFR2 HER1 TKI allow ( instance Avastin Tarceva , ) Treatment TKIs within past 4 week Patients brain metastasis Patients centrally locate squamous cell carcinoma lung Major gastrointestinal surgery may affect absorption drug Any surgery within last 4 week History thromboembolism Severe unmanageable diarrhea Subjects Part B NonSmall Cell Lung Cancer ( NSCLC ) Part B/Cohort I erlotinibnaive subject Part B/Cohort II subject experienced disease progression receive erlotinib ( erlotinibresistant subject )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Solid Tumors</keyword>
</DOC>